---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-21-000045"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2021-10-28T23:59:59+00:00"
generated_at: "2026-06-28T16:36:50.467115+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q3 revenue $747M (+15.4% YoY); non-GAAP EPS $3.71; raises FY21 guidance

## Summary
- Life Science segment revenue $373.5M (+15.3% YoY); Clinical Diagnostics $372.2M (+15.5% YoY).
- GAAP net income $3.93B ($129.96 diluted EPS) driven by $4.87B unrealized gain on Sartorius equity.
- Non-GAAP net income $112.2M ($3.71 diluted EPS) vs $90.3M ($3.00) a year ago.
- Full-year 2021 guidance: non-GAAP currency-neutral revenue growth 12-13%; operating margin ~19.5%.
- Gross margin improved to 58.6% from 56.7%; operating margin 21.0% vs 16.9%.

## SEC filing metadata
- accession: 0000012208-21-000045
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2021-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220821000045/0000012208-21-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220821000045/bio-20211028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-21-000045
- JSON: https://secwatch.observer/filing/0000012208-21-000045.json
- Plain text: https://secwatch.observer/filing/0000012208-21-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.